摘要
目的研究前列地尔(前列腺素E1脂微球制剂)联合替米沙坦在治疗早期糖尿病肾病(DN)中对超敏C反应蛋白(hsCRP)及胱抑素(CysC)水平的影响。方法收集本院门诊和住院病人71例早期DN患者,随机分为单纯前列地尔组24例,单纯替米沙坦组23例,联合用药组24例,进行12周临床观察治疗,分别比较三组血压、血糖、糖化血红蛋白(HbA1 c)、尿微量白蛋白排泄率(UAER)、hsCRP及CysC水平的变化。结果三组在治疗前各项指标无明显差异(P〉0.05);各组治疗12周后,UAER、hsCRP及CysC指标都较治疗前均有明显好转(P〈0.01);而联合组的UAER、hsCRP及CysC较另两组改善更明显(P〈0.05)。结论前列地尔联合替米沙坦治疗早期DN,能有效改善hsCRP、CysC及减少UAER,并长期维持尿蛋白于低水平,有利于延缓甚至防止糖尿病肾病的发生和发展。
Objective To evaluate the The function of Alprostadil jointly for Telm isartan on High Sensitivity CRP and Cys C in patients with early diabetic nephropathy ( DN ).Methods Seventy-one patients with early DN were randomly assigned to the pure Alprostadil group(n=24)treated on Alprostadi or the Telmisartan group(n=23)treated on telmisartan or the co-contractor group ( n=24 ) treated on Alprostadi and Telmisartan.for 1 2 weeks. Changes before and after treatment in levels of blood pressure, serHm lipids, plasma glucose, HbAlc, urine albumin excretion rate ( UAER ), hsCRP and Cys- C were observed and compared between the three groups. Results The three groups showed similar levels of the indexes at baseline(P 〉 0.05). After 12 weeks of treatment, UAER, hsCRP, Cys C were significantly improved in three groups (P 〈 0.01). The combination group showed greater improvement in UAER, hsCRP and Cys C(P 〈 0.05)compared with the another controls. Conclusion Use of Alprostadil and telmisartan in the treatment of early diabetic nephropathy can decrease the levels ofhsCRP, Cys C and microalbuminuria, And the long-term maintenance urine protein in the low level, is advantageous to the postponement even prevents diabetes nephropathy the occurrence and the development.
出处
《国际医药卫生导报》
2009年第6期56-59,共4页
International Medicine and Health Guidance News
关键词
早期糖尿病肾病
替米沙坦
前列地尔
超敏C反应蛋白
胱抑素
Early diabetic nephropathy
Alprostadil
Telmisartan
High sensitivity C-reactive protein
Cystatin C